A new CRISPR-based one-off procedure that lowers "bad" cholesterol has been approved to enter Phase I human trial. If ...

The hold followed Intellia’s voluntary pause in response to a grade 4 liver event—a case of Hy’s Law—in the ATTR-CM trial. Shortly after the regulatory hold was implemented, Intellia disclosed that ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively ...

After a patient safety signal and then death, the FDA in October 2025 placed holds on two of the company’s CRISPR programs for hereditary transthyretin amyloidosis.

The CRISPR “gene scissors” have become an important basis for genome-editing technologies in many fields, ranging from biology and medicine to agriculture and industry. A team from the Helmholtz ...

For the first time, the tools to rewrite human biology are moving from speculative fiction into regulated clinics and ...

What if a cup of coffee could help treat cancer? Researchers at the Texas A&M Health Institute of Biosciences and Technology ...

The global cell and gene therapy market is experiencing explosive growth. Key growth factors include rising chronic/genetic disease prevalence, advancements in gene editing (CRISPR) and viral vectors, ...

This article explores why absolute quantification with ddPCR technology is ideal for determining the outcomes of CRISPR ...

If you are trying to work out whether CRISPR Therapeutics is attractively priced or not, starting with the recent share performance and valuation checks can give you a clearer picture. The stock ...